A compound selected from Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; where one or two of X 1, X 2, and X 3 are N; R 1, R 2 and R 3 are independently selected from H, F, Cl, -NH 2, -NHCH 3, -N(CH 3) 2,-OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is optionally substituted C 6 -C 20 aryl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl)-(C 1 -C 6 alkyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 6 alkyl), -(C 2 -C 20 heterocyclyl)-(C 1 -C 6 alkyl), -(C 2 -C 20 heterocyclyl)-(C 3 -C 12 carbocyclyl), -(C 1 -C 20 heteroaryl)-(C 3 -C 12 carbocyclyl), or -(C 1 -C 20 heteroaryl)-C(=O)-(C 2 -C 20 heterocyclyl); R 6 is H, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -CHF 2, -NH 2, or -OH; R 7 is selected from the structures: where the wavy line indicates the site of attachment; and Y 1 and Y 2 are independently selected from CH and N, where Y 1 and Y 2 are not each N; where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3,-CH(CH 3) 2, -CH 2 CH(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH,-CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, -CH 2 OP 2, -CH 2 F, -CHF 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, -C(CH 3) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3,-CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, -CONH 2, -CONHCH 3, -CON(CH 3) 2,-C(CH 3) 2 CONH 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3, -NHS 2 CH 3, -N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH, -OCH 3,-OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2,-S 2 N(CH 3) 2, -SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, and morpholino. X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; where one or two of X 1, X 2, and X 3 are N; R 1, R 2 and R 3 are independently selected from H, F, Cl, -NH 2, -NHCH 3, -N(CH 3) 2,-OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is optionally substituted C 6 -C 20 aryl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl)-(C 1 -C 6 alkyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 6 alkyl), -(C 2 -C 20 heterocyclyl)-(C 1 -C 6 alkyl), -(C 2 -C 20 heterocyclyl)-(C 3 -C 12 carbocyclyl), -(C 1 -C 20 heteroaryl)-(C 3 -C 12 carbocyclyl), or -(C 1 -C 20 heteroaryl)-C(=O)-(C 2 -C 20 heterocyclyl); R 6 is H, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -CHF 2, -NH 2, or -OH; R 7 is selected from the structures: